Viking Therapeutics (LTS:0VQA) Debt-to-Asset : 0.00 (As of Dec. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Viking Therapeutics Debt-to-Asset?

Viking Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was $0.49 Mil. Viking Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was $0.63 Mil. Viking Therapeutics's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2024 was $908.32 Mil. Viking Therapeutics's debt to asset for the quarter that ended in Dec. 2024 was 0.00.

Viking Therapeutics Debt-to-Asset Historical Data

The historical data trend for Viking Therapeutics's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Viking Therapeutics Debt-to-Asset Chart

Viking Therapeutics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Debt-to-Asset

Get a 7-Day Free Trial

0.01

Viking Therapeutics Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Debt-to-Asset	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Viking Therapeutics's Debt-to-Asset

For the Biotechnology subindustry, Viking Therapeutics's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Viking Therapeutics's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Viking Therapeutics's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Viking Therapeutics's Debt-to-Asset falls into.

Save Embed

;

Save Embed

;

Viking Therapeutics Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Viking Therapeutics's Debt-to-Asset for the fiscal year that ended in Dec. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0.489	+	0.63)	/	908.321
	=	0.00

Viking Therapeutics's Debt-to-Asset for the quarter that ended in Dec. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0.489	+	0.63)	/	908.321
	=	0.00

Viking Therapeutics (LTS:0VQA) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Viking Therapeutics Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Viking Therapeutics's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Viking Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Viking Therapeutics Inc (LTS:0VQA) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

VKTX:USA 1VT:Germany 1VT:Germany

Address

9920 Pacific Heights Boulevard, Suite 350, San Diego, CA, USA, 92121

Website

https://www.vikingtherapeutics.com

Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.

Viking Therapeutics Headlines

No Headlines